
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. demonstrated an improved financial outlook as both segments reported adjusted operating margin expansions, with the Life Sciences (LS) segment achieving 13.1% and the Bioprocessing (BP) segment reaching 26.6% due to fixed cost leverage, volume growth, and cost transformation initiatives. The company's 4Q organic revenue grew by 1.0% to $1.69 billion, supported by a resurgence in bioprocessing driven by strong order intake, while management highlighted resilience in the LS business through new contract wins and customer relationship expansions. As Avantor operates in a favorable healthcare market and anticipates further margin expansion, the positive trajectory in financial metrics and revenue growth suggests a strong potential for multiple expansion in the future.
Bears say
Avantor Inc. faces a challenging outlook primarily due to a slowdown in purchasing from small biotech firms, which could lead to revenue declines in that sub-segment. In their recent financials, the education and government sectors experienced a low-single-digit organic decline, while advanced technologies and applied materials also saw a mid-single-digit organic decline, indicating weaker demand across key markets. Additionally, prolonged inventory destocking at customer levels raises concerns about future guidance and estimates, further contributing to a negative sentiment regarding the company's financial performance.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares